No further excuse to delay digital regulatory infrastructure for medicines after Covid-19 pandemic

Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care

AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” press release.

Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks

EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed

All routes to healthcare efficiency include biosimilar medicines

EU Pharma Strategy: Success depends on access to Generic, Biosimilar and Value Added Medicines

IGBA Launches First Global Biosimilars Week

European Health Union – first step to greater EU solidarity in health crisis situations

Joint EU-UK pharmaceutical industry response to Specialised Committee outcome